{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:21Z","timestamp":1790697861197,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["19-33-90145"],"award-info":[{"award-number":["19-33-90145"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["20-33-70089"],"award-info":[{"award-number":["20-33-70089"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejmech.2021.113752","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:24:21Z","timestamp":1628400261000},"page":"113752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["PSMA-targeted low-molecular double conjugates for diagnostics and therapy"],"prefix":"10.1016","volume":"225","author":[{"given":"Stanislav A.","family":"Petrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay Y.","family":"Zyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0346","authenticated-orcid":false,"given":"Aleksei E.","family":"Machulkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Beloglazkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Majouga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113752_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012118776068","article-title":"PSMA theranostics: current status and future directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.113752_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA. Canc. J. Clin."},{"key":"10.1016\/j.ejmech.2021.113752_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2021.113752_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2021.113752_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2021.113752_bib6","first-page":"10","article-title":"Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Sun","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2021.113752_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/med.21508","article-title":"Targeting prostate cancer: prostate-specific membrane antigen based diagnosis and therapy","volume":"39","author":"W\u00fcstemann","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bmcl.2009.10.061","article-title":"Bioisosterism of urea-based GCPII inhibitors: synthesis and structure\u2013activity relationship studies","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113752_bib9","first-page":"927\u2014935","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib10","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib11","first-page":"2321","article-title":"Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization","volume":"57","author":"Kawakami","year":"1997","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib12","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2021.113752_bib13","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib14","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","author":"Liu","year":"1997","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.ejmech.2021.113752_bib16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.humpath.2009.06.003","article-title":"Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers","volume":"40","author":"Haffner","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2021.113752_bib17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib18","first-page":"1","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Canc. Cell Int."},{"key":"10.1016\/j.ejmech.2021.113752_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","article-title":"Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature","volume":"24","author":"Samplaski","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejmech.2021.113752_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Pandit-Taskar","year":"2015","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease\u2014current status and future perspectives","volume":"45","author":"Backhaus","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.113752_bib22","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neuroscience.2006.10.022","article-title":"Expression of glutamate carboxypeptidase II in human brain","volume":"144","author":"\u0160\u00e1cha","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2021.113752_bib24","first-page":"1199","article-title":"Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2","volume":"31","author":"Goodman","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2021.113752_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mvr.2006.03.004","article-title":"Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature","volume":"72","author":"Anilkumar","year":"2006","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib26","first-page":"2645","article-title":"Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity","volume":"63","author":"Anilkumar","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib27","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113752_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/1061186X.2016.1154564","article-title":"Small-molecule PSMA ligands. Current state, SAR and perspectives","volume":"24","author":"Machulkin","year":"2016","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ejmech.2021.113752_bib29","first-page":"4170","article-title":"Design and Pharmacological Activity of Phosphinic Acid Based NAALADase","volume":"44","author":"Jackson","year":"2001","journal-title":"Inhibitors"},{"key":"10.1016\/j.ejmech.2021.113752_bib30","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1016\/j.bmc.2004.06.031","article-title":"Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates","volume":"12","author":"Maung","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1021\/jm020515w","article-title":"Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor","volume":"46","author":"Majer","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib32","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1021\/jm051019l","article-title":"Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1\u2032 side chain","volume":"49","author":"Majer","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib33","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1021\/jm300488m","article-title":"Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds","volume":"55","author":"Stoermer","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/jm401703a","article-title":"\u03b4-thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors","volume":"57","author":"Ferraris","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib36","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acs.jmedchem.5b01268","article-title":"Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)","volume":"59","author":"Yang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2021.113752_bib38","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","article-title":"Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA","volume":"27","author":"Ray Banerjee","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/pros.22789","article-title":"Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker","volume":"74","author":"Huang","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2021.113752_bib41","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-Targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbrc.2009.10.017","article-title":"A\u00a0low molecular weight PSMA-based fluorescent imaging agent for cancer","volume":"390","author":"Chen","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.113752_bib43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Benesov\u00e1","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib44","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"68Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga\u2013Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2021.113752_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bju.13540","article-title":"Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer","volume":"119","author":"van Leeuwen","year":"2017","journal-title":"BJU Int."},{"key":"10.1016\/j.ejmech.2021.113752_bib47","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.bmcl.2014.03.066","article-title":"Structural characterization of P1\u2032-diversified urea-based inhibitors of glutamate carboxypeptidase II","volume":"24","author":"Pavlicek","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113752_bib48","doi-asserted-by":"crossref","first-page":"126894","DOI":"10.1016\/j.bmcl.2019.126894","article-title":"Design and synthesis of a novel BODIPY-labeled PSMA inhibitor","volume":"30","author":"Son","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113752_bib49","first-page":"1","article-title":"Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA)","volume":"8","author":"Shen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113752_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2016.08.048","article-title":"Discovery of PSMA-specific peptide ligands for targeted drug delivery","volume":"513","author":"Jin","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2021.113752_bib51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1535-7163.597.3.5","article-title":"Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen","volume":"3","author":"Lupold","year":"2004","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113752_bib52","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1073\/pnas.0610298104","article-title":"Biomimetic amplification of nanoparticle homing to tumors","volume":"104","author":"Simberg","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2021.113752_bib53","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/thno.40482","article-title":"Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity","volume":"10","author":"Deberle","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib54","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib55","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1158\/1535-7163.MCT-14-0422","article-title":"Development of targeted near-infrared imaging agents for prostate cancer","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113752_bib56","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1039\/C6CC09781B","article-title":"PSMA-targeted contrast agents for intraoperative imaging of prostate cancer","volume":"53","author":"Bao","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.113752_bib57","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1021\/acs.bioconjchem.6b00222","article-title":"Design of a small-molecule drug conjugate for prostate cancer targeted theranostics","volume":"27","author":"Kumar","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41391-018-0055-8","article-title":"Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis","volume":"21","author":"Tan","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejmech.2021.113752_bib59","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jbm.b.34208","article-title":"Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells","volume":"107","author":"Sokol","year":"2019","journal-title":"J.\u00a0Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.ejmech.2021.113752_bib60","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.7150\/thno.14860","article-title":"Versatile nanosystem-based cancer theranostics: design inspiration and predetermined routing","volume":"6","author":"Opoku-Damoah","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113752_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10967-019-06800-6","article-title":"Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer","volume":"322","author":"Vahidfar","year":"2019","journal-title":"J.\u00a0Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ddr.21758","article-title":"Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: a state-of-the-art review","volume":"82","author":"Kunjiappan","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/molecules22040523","article-title":"Metal-based PSMA radioligands","volume":"22","author":"Gourni","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113752_bib66","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/ajoc.201900329","article-title":"Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer","volume":"8","author":"Kwon","year":"2019","journal-title":"Asian J. Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib67","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib68","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib69","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.7150\/thno.36739","article-title":"PSMA-targeting agents for radio- and fluorescenceguided prostate cancer surgery","volume":"9","author":"Derks","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2967\/jnumed.114.149526","article-title":"Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?","volume":"56","author":"Watanabe","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib71","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fbioe.2019.00197","article-title":"Nanotheranostics targeting the tumor microenvironment","volume":"7","author":"Roma-Rodrigues","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.113752_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/smll.201900631","article-title":"Sequential targeting TGF-\u03b2 signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer","volume":"15","author":"Pei","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.ejmech.2021.113752_bib74","doi-asserted-by":"crossref","first-page":"1802070","DOI":"10.1002\/advs.201802070","article-title":"Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery","volume":"6","author":"Chen","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2021.113752_bib75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2019.06.007","article-title":"Intratumoral fate of functional nanoparticles in response to microenvironment factor: implications on cancer diagnosis and therapy","volume":"143","author":"Peng","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib76","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1002\/anie.200602251","article-title":"An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform","volume":"45","author":"Bagalkot","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113752_bib77","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1568026611313080008","article-title":"PET imaging in prostate cancer: focus on prostate-specific membrane antigen","volume":"13","author":"Mease","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib79","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status","volume":"5","author":"L\u00fctje","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib80","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib81","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib82","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinchem\/35.5.755","article-title":"Current concepts in proteinuria","volume":"35","author":"Waller","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib83","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib84","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Willhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejmech.2021.113752_bib85","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody\u2013drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113752_bib86","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jnci\/djj070","article-title":"Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers","volume":"98","author":"Dreher","year":"2006","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2021.113752_bib87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0006-3495(99)76911-0","article-title":"Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations","volume":"77","author":"Pluen","year":"1999","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2021.113752_bib88","first-page":"2747","article-title":"Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the \u201cbinding site barrier","volume":"52","author":"Weinstein","year":"1992","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib89","first-page":"489","article-title":"Challenges in the development and manufacturing of antibody-drug conjugates","volume":"vol. 899","author":"Meilert","year":"2012"},{"key":"10.1016\/j.ejmech.2021.113752_bib90","first-page":"76","article-title":"Consideration for the safe and effective manufacturing of antibody drug conjugates","volume":"30","author":"Rohrer","year":"2012","journal-title":"Chim. Oggi\/Chemistry Today."},{"key":"10.1016\/j.ejmech.2021.113752_bib91","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody\u2013drug conjugates and small molecule\u2013drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2021.01.010","article-title":"Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies","volume":"333","author":"Sun","year":"2021","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.113752_bib93","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acsnano.9b08133","article-title":"Nanomaterials for nanotheranostics: tuning their properties according to disease needs","volume":"14","author":"Wong","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2021.113752_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13080173","article-title":"Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy","volume":"13","author":"Judmann","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.113752_bib96","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molmed.2020.12.006","article-title":"Multivalent probes in molecular imaging: reality or future?","volume":"27","author":"B\u00f6hmer","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib97","author":"Liolios"},{"key":"10.1016\/j.ejmech.2021.113752_bib98","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/biom9090421","article-title":"Tumor uptake of triazine dendrimers decorated with four, sixteen, and sixty-four PSMA-targeted ligands: passive versus active tumor targeting","volume":"9","author":"Lim","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2021.113752_bib99","doi-asserted-by":"crossref","first-page":"9258","DOI":"10.1021\/acs.jmedchem.0c00291","article-title":"Bivalent inhibitors of prostate-specific membrane antigen conjugated to desferrioxamine B squaramide labeled with zirconium-89 or gallium-68 for diagnostic imaging of prostate cancer","volume":"63","author":"Noor","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib100","author":"Banerjee"},{"key":"10.1016\/j.ejmech.2021.113752_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-219X-2-23","article-title":"A\u00a0dimerized urea-based inhibitor of the prostatespecific membrane antigen for 68Ga-PET imaging of prostate cancer","volume":"2","author":"Sch\u00e4fer","year":"2012","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib102","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.bmcl.2018.01.047","article-title":"Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation","volume":"28","author":"Do Kwon","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113752_bib103","author":"Mitran"},{"key":"10.1016\/j.ejmech.2021.113752_bib104","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acs.bioconjchem.5b00687","article-title":"Novel bispecific PSMA\/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer","volume":"27","author":"Liolios","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib105","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/pharmaceutics11070358","article-title":"Synthesis and preclinical evaluation of radio-iodinated GRPR\/PSMA bispecific heterodimers for the theranostics application in prostate cancer","volume":"11","author":"Abouzayed","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2021.113752_bib106","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.nucmedbio.2014.01.001","article-title":"Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr\/PSMA) of prostate cancer","volume":"41","author":"Bandari","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2021.113752_bib107","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jmedchem.0c01785","article-title":"Development of heterobivalent theranostic probes having high affinity\/selectivity for the GRPR\/PSMA","volume":"64","author":"Bandari","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12070614","article-title":"Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer\u2014optimization of the affinity towards PSMA by linker modification in murine model","volume":"12","author":"Lundmark","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2021.113752_bib109","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","article-title":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","volume":"74","author":"Eder","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2021.113752_bib110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNM.0000000000000966","article-title":"Synthesis and preclinical evaluation of the 177 Lu-DOTA-PSMA(inhibitor)-Lys 3 -bombesin heterodimer designed as a radiotheranostic probe for prostate cancer","volume":"40","author":"Escudero-Castellanos","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ejmech.2021.113752_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659095","article-title":"A\u00a0theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR","author":"Arndt","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejmech.2021.113752_bib112","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2016.04.033","article-title":"Design, synthesis and biological evaluation of PSMA\/hepsin-targeted heterobivalent ligands","volume":"118","author":"Subedi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib113","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/acs.bioconjchem.9b00252","article-title":"Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity","volume":"30","author":"V Popik","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib114","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/bc4005377","article-title":"Heterobivalent agents targeting PSMA and integrin - \u03b1v\u03b23","volume":"25","author":"Shallal","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib115","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s10967-017-5555-9","article-title":"Preparation and in\u00a0vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical","volume":"314","author":"Escudero-Castellanos","year":"2017","journal-title":"J.\u00a0Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib116","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/ajoc.201900329","article-title":"Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer","volume":"8","author":"Kwon","year":"2019","journal-title":"Asian J. Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib117","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymeth.2017.06.026","article-title":"PSMA ligands in prostate cancer \u2013 probe optimization and theranostic applications","volume":"130","author":"L\u00fctje","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2021.113752_bib118","first-page":"1","article-title":"A\u00a0structure-activity relationship study of bimodal BODIPY-labeled PSMA-targeting bioconjugates","author":"Stemler","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113752_bib119","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1535-7163.MCT-15-0722","article-title":"Theranostic agents for photodynamic therapy of prostate cancer by targeting prostate-specific membrane antigen","volume":"15","author":"Wang","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113752_bib120","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/acs.bioconjchem.8b00636","article-title":"Tuning pharmacokinetics to improve tumor accumulation of a prostate-specific membrane antigen-targeted phototheranostic agent","volume":"29","author":"Harmatys","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jphotobiol.2016.12.018","article-title":"A\u00a0PSMA-targeted theranostic agent for photodynamic therapy","volume":"167","author":"Chen","year":"2017","journal-title":"J.\u00a0Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.ejmech.2021.113752_bib122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2967\/jnumed.119.232330","article-title":"Prostate-specific membrane antigen\u2013guided surgery","volume":"61","author":"Maurer","year":"2020","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib123","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-specific membrane antigen ligands for imaging and therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib124","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/bc2002715","article-title":"Targeted, activatable, in\u00a0vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody\u2013indocyanine green (ICG) conjugate","volume":"22","author":"Nakajima","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib125","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-15-0503","article-title":"Fluorescent image-guided surgery with an anti-Prostate Stem Cell Antigen (PSCA) diabody enables targeted resection of mouse prostate cancer xenografts in real time","volume":"22","author":"Sonn","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib126","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3762\/bjoc.14.244","article-title":"Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer","volume":"14","author":"Sengupta","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib127","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2967\/jnumed.117.201293","article-title":"PSMA-11\u2013Derived dual-Labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-Guided surgery of prostate cancer","volume":"59","author":"Baranski","year":"2018","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib128","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1002\/anie.201102872","article-title":"Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen","volume":"50","author":"Banerjee","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113752_bib129","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.119.233064","article-title":"Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction","volume":"61","author":"Hensbergen","year":"2020","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.118.212720","article-title":"Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer","volume":"60","author":"Schottelius","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib131","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.8b00240","article-title":"18F-Positron emitting\/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management","volume":"61","author":"Kommidi","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib132","author":"Derks"},{"key":"10.1016\/j.ejmech.2021.113752_bib133","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acschembio.9b00160","article-title":"A\u00a0fluorescent, [18F]-Positron-Emitting agent for imaging prostate-specific membrane antigen allows genetic reporting in adoptively transferred, genetically modified cells","volume":"14","author":"Guo","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113752_bib134","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2967\/jnumed.118.213488","article-title":"New developments in dual-labeled molecular imaging agents","volume":"60","author":"Vargas","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","article-title":"The impact of 68Ga-PSMA PET\/CT and PET\/MRI on the management of prostate cancer","volume":"130","author":"Hoffmann","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.ejmech.2021.113752_bib136","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2214\/AJR.16.16181","article-title":"Dual PET and near-infrared fluorescence imaging probes as tools for imaging in oncology","volume":"207","author":"An","year":"2016","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.ejmech.2021.113752_bib137","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/acs.bioconjchem.9b00758","article-title":"Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers?","volume":"31","author":"Hensbergen","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib138","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1039\/b809537j","article-title":"Simplified syntheses of complex multifunctional nanomaterials","author":"Garanger","year":"2008","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.113752_bib139","series-title":"Modular Synthesis of Dual-And Tri-modal Targeted Molecular Imaging Agents","author":"Schug","year":"2020"},{"issue":"12","key":"10.1016\/j.ejmech.2021.113752_bib140","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1021\/bc3003919","article-title":"Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen","volume":"23","author":"Chen","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib141","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1042\/BJ20150942","article-title":"New photosensitizers for photodynamic therapy","volume":"473","author":"Abrahamse","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2021.113752_bib142","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jlcr.3884","article-title":"Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer","volume":"64","author":"Kim","year":"2021","journal-title":"J.\u00a0Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2021.113752_bib143","first-page":"1","article-title":"Small molecule, multimodal, [18F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study","author":"Aras","year":"2021","journal-title":"Clin. Genitourin. Canc."},{"key":"10.1016\/j.ejmech.2021.113752_bib144","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11307-014-0747-y","article-title":"Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation","volume":"16","author":"L\u00fctje","year":"2014","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2021.113752_bib145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib146","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5603\/NMR.2016.0019","article-title":"Limitations and pitfalls of 99mTc-EDDA\/HYNIC-TOC (Tektrotyd) scintigraphy","volume":"19","author":"Garai","year":"2016","journal-title":"Nucl. Med. Rev. Cent. E Eur."},{"key":"10.1016\/j.ejmech.2021.113752_bib147","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1021\/acs.chemrev.8b00281","article-title":"Radioactive transition metals for imaging and therapy","volume":"119","author":"Boros","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib148","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive main group and rare Earth metals for imaging and therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib149","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40336-017-0235-x","article-title":"Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook","volume":"5","author":"Bugby","year":"2017","journal-title":"Clin. Transl. Imaging"},{"key":"10.1016\/j.ejmech.2021.113752_bib150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.semnuclmed.2017.05.007","article-title":"Clinical applications of radiolabeled peptides for PET","volume":"47","author":"Jackson","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib151","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1016\/j.bmcl.2011.06.107","article-title":"Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates","volume":"21","author":"Dadwal","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113752_bib152","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.7150\/thno.23335","article-title":"Tumor-targeted dual-modality imaging to improve intraoperative visualization of clear cell renal cell carcinoma: a first in man study","volume":"8","author":"Hekman","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.113752_bib153","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.106.036020","article-title":"Indication for different mechanisms of kidney uptake of radiolabeled peptides","volume":"48","author":"Gotthardt","year":"2007","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib154","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.addr.2010.09.011","article-title":"Approaches using molecular imaging technology - use of PET in clinical microdose studies","volume":"63","author":"Wagner","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113752_bib155","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00259-016-3372-y","article-title":"Fluorescence guided surgery and tracer-dose, fact or fiction?","volume":"43","author":"KleinJan","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.113752_bib156","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1148\/radiol.2463070962","article-title":"Imaging of lymph flow in breast cancer patients after microdose administration of a Methods\u00a0: feasibility study","volume":"246","author":"Sevick-Muraca","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.ejmech.2021.113752_bib157","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.118.219824","article-title":"Proceedings: pathways for successful translation of new imaging agents and modalities\u2014phase III studies","volume":"60","author":"Gambhir","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib158","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/anie.201310709","article-title":"A\u00a0small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors","volume":"53","author":"Krall","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113752_bib159","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/molecules25245784","article-title":"Polypeptide-based molecular platform and its docetaxel\/sulfo-cy5-containing conjugate for targeted delivery to prostate specific membrane antigen","volume":"25","author":"Petrov","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113752_bib160","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2967\/jnumed.119.234922","article-title":"Radiohybrid ligands: a novel tracer concept exemplified by 18 F- or 68 Ga-labeled rhPSMA inhibitors","volume":"61","author":"Wurzer","year":"2020","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib161","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-Carboxy-5-[(6-[ 18 F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [ 18 F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib162","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2967\/jnumed.116.181768","article-title":"Preclinical evaluation of 18 F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging","volume":"58","author":"Cardinale","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib163","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-020-00740-z","article-title":"Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics","volume":"10","author":"Wurzer","year":"2020","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib164","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2967\/jnumed.120.252114","article-title":"Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers","volume":"62","author":"Tolvanen","year":"2021","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-021-00124-1","article-title":"Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?","volume":"6","author":"Felber","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.ejmech.2021.113752_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph12010018","article-title":"[ 177 Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in\u00a0vitro autoradiography","volume":"12","author":"T\u00f6nnesmann","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.113752_bib167","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib168","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cbic.201900632","article-title":"Toward 18 F-labeled theranostics: a single agent that can Be labeled with 18 F, 64 Cu, or 177 Lu","volume":"21","author":"Lepage","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2021.113752_bib169","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1016\/j.biomaterials.2010.02.030","article-title":"Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2021.113752_bib170","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.nano.2018.04.011","article-title":"Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA)","volume":"14","author":"Patil","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113752_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.01436","article-title":"Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113752_bib172","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.scib.2019.12.024","article-title":"Janus \u03b3-Fe2O3\/SiO2-based nanotheranostics for dual-modal imaging and enhanced synergistic cancer starvation\/chemodynamic therapy","volume":"65","author":"Zhang","year":"2020","journal-title":"Sci. Bull."},{"key":"10.1016\/j.ejmech.2021.113752_bib173","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/onc.2013.497","article-title":"Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy","volume":"33","author":"Drake","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113752_bib174","series-title":"Chemistry of Peptide Synthesis","isbn-type":"print","author":"Benoiton","year":"2006","ISBN":"https:\/\/id.crossref.org\/isbn\/9781574444544"},{"key":"10.1016\/j.ejmech.2021.113752_bib175","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/454503","article-title":"18F-Labeled silicon-based fluoride acceptors: potential opportunities for novel positron emitting radiopharmaceuticals","volume":"2014","author":"Bernard-Gauthier","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2021.113752_bib176","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1002\/anie.200600795","article-title":"18F-labeling of peptides by means of an organosilicon-based fluoride acceptor","volume":"45","author":"Schirrmacher","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.113752_bib177","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1158\/0008-5472.CAN-10-1584","article-title":"Novel matrix metalloproteinase inhibitor [18F]marimastat- aryltrifluoroborate as a probe for in\u00a0vivo positron emission tomography imaging in cancer","volume":"70","author":"Auf Dem Keller","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113752_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-219X-3-36","article-title":"Radiofluorination using aluminum-fluoride (Al18F)","volume":"3","author":"McBride","year":"2013","journal-title":"EJNMMI Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421006012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:55Z","timestamp":1759329295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421006012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":177,"alternative-id":["S0223523421006012"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113752","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-targeted low-molecular double conjugates for diagnostics and therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113752"}}